Tehran University of Medical Sciences Iranian Journal of Public Health 2251-6085 52 11 2023 10 29 2260 2271 Hassane Gazzaz 1. Clinical, Metabolic and Molecular Biochemistry Team, Faculty of Medicine and Pharmacy, Mohammed V University,10100 Rabat, Morocco 2. Higher Institute of Nursing Professions and Health Techniques of Marrakech, annex of Safi, Morocco Maha El Habchi Research Laboratory of Psychiatry, Medical Psychology and History of Medicine, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco Mohammed El Feniche Laboratory of Biostatistics, Clinical Research and Epidemiology, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco Yassine El Aatik Research Laboratory of Psychiatry, Medical Psychology and History of Medicine, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco Abdelghani El Ouardi Research Laboratory of Psychiatry, Medical Psychology and History of Medicine, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco Ahmed Ameur Department of Urology, Military Hospital Mohammed V, 10045 Rabat, Morocco Abdellah Dami 1. Clinical, Metabolic and Molecular Biochemistry Team, Faculty of Medicine and Pharmacy, Mohammed V University,10100 Rabat, Morocco 2. Department of Biochemistry and Toxicology, Military Hospital Mohammed V, 10045 Rabat, Morocco 2023 02 25 2023 10 29 Background: Accurate and non-invasive diagnostic and prognostic markers are necessary to improve patient outcomes. MicroRNAs have been proposed as relatively non-invasive and pertinent biomarkers. miR-93 has been studied for its potential as a diagnostic and prognostic marker in prostate cancer (PCa), but findings from individual studies are inconsistent. We conducted a meta-analysis of its overall differential expression in 13 PCa studies and a bioinformatics analysis to provide a comprehensive appraisal of its diagnostic and prognostic role. Methods: We searched all published papers on miR-93 expression in PCa up to Nov 30, 2022 using PubMed, Science Direct, Web of Science, Cochrane Central Register of Controlled Trials databases. We used RevMan software to Meta-analyze the included literature. A bioinformatics analysis of genes and pathways that might be target to the effect of the mature miR-93-5p was carried out. Results: The pooled standardized mean difference (SMD) of miR-93 expression in PCa, its area under the curve (AUC) and hazard ratio (HR) were 1.26, 95% CI [-0.34–2.86], 0.84, 95% CI [0.76 –0.93] and 1.67, 95% CI [0.98, 2.84] respectively. Bioinformatics analysis revealed that mature miR-93-5p may regulate genes such as SMAD1, SMAD7 and MAPK and the PI3K-Akt signaling pathways. Conclusion: miR-93 has significant diagnostic and prognostic value in PCa. These findings highlight the potential of miR-93 as a non-invasive biomarker for PCa and may contribute to earlier detection and prognostic assessment. The target genes and signaling pathways regulated by miR-93 may provide insights into the underlying molecular mechanisms of PCa. https://ijph.tums.ac.ir/index.php/ijph/article/view/31327 https://ijph.tums.ac.ir/index.php/ijph/article/download/31327/8078